Company intelligence / Profile preview

HH InRe

United States

Ownership: Private
Development stage: Other

Overview

Inipharm is conducting a Phase 1 clinical trial, including MASH patients, of INI-822, a first-in-class small molecule inhibitor of HSD17B13. Preclinical data show reduced fibrotic markers, improved liver enzymes, and replicated lipidomic changes seen with protective HSD17B13 variants.[1]

Therapeutic areas: Gastroenterology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on HH InRe.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HH InRe.

Explore the full profile